SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

9 Sep 2010 11:48

RNS Number : 4249S
Nomura Code Securities Limited
09 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

08 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.0

85,953

0.0

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

0.0

85,953

0.0

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord shares

Purchase

10,000

11.75 p

Ord shares

Purchase

25,000

12 p

Ord shares

Purchase

37,699

12.012 p

Total

Purchases:

72,699

Ord shares

Sale

25,000

11.7148 p

Ord shares

Sale

10,000

11.75 p

Ord shares

Sale

9,800

12 p

Ord shares

Sale

5,372

12.0663 p

Ord shares

Sale

119,000

12.25 p

Total

Sales:

169,172

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

09 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUKSRRRBAKRAR
Date   Source Headline
26th Nov 20217:00 amRNSUpdate on AIM Delisting
25th Nov 20215:30 pmRNSSilence Therapeutics
16th Nov 20217:00 amRNSThird Quarter 2021 Financial Results
11th Nov 20217:00 amRNSSilence to Present at Jefferies London Conference
10th Nov 20217:00 amRNSHolding(s) in Company
5th Nov 20217:00 amRNSNew Key Shareholder
1st Nov 20215:33 pmRNSResult of General Meeting
1st Nov 20214:49 pmRNSTotal Voting Rights
28th Oct 20214:02 pmRNSHolding(s) in Company
21st Oct 20211:30 pmRNSSilence Provides Pipeline Updates at 2021 R&D Day
15th Oct 20217:05 amRNSProposed Cancellation of Trading on AIM
15th Oct 20217:00 amRNSSilence and Hansoh Pharma Announce Collaboration
8th Oct 20217:00 amRNSBlock Listing Return
8th Oct 20217:00 amRNSTotal Voting Rights
7th Oct 20217:00 amRNSSilence Therapeutics to host R&D day
28th Sep 20217:00 amRNSChardan Genetic Medicines Conference Participation
8th Sep 20214:03 pmRNSHolding(s) in Company
8th Sep 20214:00 pmRNSHolding(s) in Company
1st Sep 20217:00 amRNSSilence Appoints Senior VP of BD, AM and NPD.
25th Aug 20217:00 amRNSSilence to Participate in Investor Conferences
12th Aug 20217:00 amRNSSilence Therapeutics Report Half-Year 2021 Results
6th Aug 202112:15 pmRNSHolding(s) in Company
6th Aug 202112:13 pmRNSHolding(s) in Company
5th Aug 20212:57 pmRNSTotal Voting Rights
15th Jul 20217:00 amRNSNotice of half year results
15th Jun 20215:54 pmRNSResults of Annual General Meeting
7th Jun 20217:00 amRNSSilence to present SL124 data at EHA
25th May 20217:00 amRNS$40m Payment from AstraZeneca for Collaboration
19th May 20217:00 amRNSPhase 1 Study in Healthy Volunteers Positive Data
12th May 20217:00 amRNSSilence attends RBC Global Healthcare Conference
7th May 20217:00 amRNSNotice of AGM
4th May 20217:00 amRNSSilence Support International Thalassemia Day
30th Apr 20214:12 pmRNSHolding(s) in Company
29th Apr 20215:58 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSFirst patient dosed in GEMINI II
28th Apr 20217:00 amRNSSilence Achieves Research Milestone Payment
27th Apr 20217:00 amRNSGrant of Employee Options
19th Apr 20217:00 amRNSPurchase of ADS and PDMR Shareholding
15th Apr 20217:00 amRNSPublication in Cardiovascular Research
7th Apr 20217:00 amRNSSilence to Present at Virtual Needham Conference
30th Mar 20216:13 pmRNSSilence Therapeutics Publication of Annual Report
30th Mar 20219:04 amRNSREPLACEMENT Silence Reports Full-year 2020 Results
30th Mar 20217:00 amRNSSilence Reports Full-year 2020 Results
26th Mar 20217:00 amRNSBlock Listing Application
4th Mar 20217:29 amRNSSilence presents at Barclays Healthcare Conference
1st Mar 20217:00 amRNSNotice of Annual Results
26th Feb 20217:00 amRNSSilence & Mallinckrodt Initiate Work on 3rd Target
24th Feb 20213:09 pmRNSHolding(s) in Company
22nd Feb 20217:00 amRNSSilence to Partake in March Investor Conferences
18th Feb 20217:00 amRNSSilence to present at SVB Leerink Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.